Video transcript
On Screen Text
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Important Safety Information
- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
Please see additional Important Safety Information at the end of this video and full Prescribing Information at the link above.
Audio
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Important Safety Information
- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
On Screen Text
Amar Safdar, MD
Infectious Disease Specialist
Clinical Associate Professor of Medicine
Houston, TX
Audio
My name is Amar Safdar. I am an infectious disease specialist. I practice in Houston, Texas.
Lower Third Text
Dr. Safdar has been compensated by GSK for participation in this program.
ON SCREEN TEXT
What are vaccine recommendations and referrals?
Audio
As the vaccination rate in the US is relatively low in patients who are eligible for a given vaccine.1 RSV is no different.2
So the reason why patients, adult patients do not get vaccination, is one, they don't know the vaccine exists. Two, their healthcare provider has not provided the patient the information that is needed.
Compliance, or lack thereof, is a serious issue with vaccination.1
Lower Third Text
RSV= respiratory syncytial virus
ON SCREEN TEXT
What role does education play in an RSV recommendation?
AUDIO
I think patient education is truly the—the center of this issue, provide the patient with the risk of such an infection, which is RSV in older individuals that are 60 or older, and those with co-morbidities. But also, the severity of illness that can potentially happen with such an infection.2
A strong recommendation has a positive impact on patients to receive such a vaccination.
Education of patients on risk based on their age, and their underlying condition, that increases the risk of severe RSV infection, really provides the cornerstone of educating the patient, and providing them meaningful clinical information regarding the benefit of receiving a vaccine.3
It will be very helpful to bring that into discussion with the patient, to improve compliance, so patients understand the benefit of receiving RSV vaccination.
I think going into detail, telling the patient, and explaining how this will impact their life, I think, it's—it's quite important.
Lower Third Text
RSV=respiratory syncytial virus
ON SCREEN TEXT
How do you ensure your patients receive an RSV vaccine?
AUDIO
Follow-up is important to ensure that patient has received the vaccine, and in the event that patient has not been vaccinated, assistance in scheduling vaccination is important.
Those that are hospitalized, those that are residents of long-term care facilities, like skilled nursing facility or a nursing home, a partnership with inpatient pharmacy, would improve compliance.
If the outpatient office is not set up to administer vaccines, then retail pharmacies that are convenient for the patient are important.
RSV vaccinations provide a preventive option that didn't exist before. And now, we have an option to prevent an infection that can potentially reduce the risk of serious illness due to respiratory syncytial virus.3
Lower Third Text
RSV=respiratory syncytial virus
ON SCREEN TEXT
Important Safety Information (continued)
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients
Please see full Prescribing Information at the link above.
AUDIO
Important Safety Information (continued)
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients
Please see full Prescribing Information at the link above.
ON SCREEN TEXT
Thank you for watching.
To learn more about AREXVY, visit AREXVYhcp.com
References: 1. Vaccination coverage among adults in the United States, National Healthcare Interview Survey, 2021. Centers for Disease Control and Prevention. Accessed January 26, 2024. http://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2021.html 2. RSV in older adults and adults with chronic medical conditions. Centrers for Disease Control and Prevention. Accessed January 26, 2024. http://www.cdc.gov/rsv/high-risk/older-adults.html 3. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR. 2023;72(29):793-801. Doi:10.15585/mmwr.mm7229a4 4. Prescribing Information for AREXVY.
Lower Third Text
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
GSK
Intended for US healthcare professionals only.
Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK or licensor.
PMUS-RSAVID240027 August 2024
Produced in USA.
close